MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
$295,683K
Free Cash flow
$28,746K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Proceeds from sale of lab produc...
Sales of marketable securities
Gain on sale of lab products bus...
Others
Negative Cash Flow Breakdown
Gain on sale of lab products bus...
Personnel cost
Other segment items
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Total revenue
131,948
117,700
108,386
100,055
Cost of test services, product, and patient and digital solutions-Service
15,516
16,521
16,202
14,058
Cost of test services, product, and patient and digital solutions-Product
4,327
4,233
6,233
5,131
Cost of test services, product, and patient and digital solutions-Patient And Digital Solutions
14,447
11,412
11,684
10,050
Personnel cost
49,033
42,188
37,288
33,915
Professional and legal fees
5,861
7,912
9,126
10,307
Research materials and clinical trials expense
4,088
3,831
1,175
1,791
Depreciation and amortization expense
2,057
3,119
3,112
3,020
Stock-based compensation expense
10,615
9,767
8,091
8,418
Litigation settlement expense
0
-600
0
0
Business development and portfolio optimization expense
11,078
3,357
-
-
Transformational initiative costs
0
-
429
2,395
Gain on sale of lab products business
112,966
-
-
-
Other segment items
18,991
13,860
21,168
13,179
Interest income, net
1,735
1,909
2,014
2,013
Net income (loss)
110,636
2,809
-4,108
1,675
Stock-based compensation
10,654
9,803
8,091
8,418
Asset impairments and write-downs
-
-
0
-
Impairment of intangible asset and associated construction in progress
-
-
0
2,258
Depreciation and amortization
2,811
3,899
3,882
3,814
Amortization of right-of-use assets
1,237
1,419
1,378
1,349
Realized gain on sale of long-term marketable equity securities, net
-
-
0
-
Loss on disposal of asset
-
-119
-48
-
Gain on settlement of obligation and recovery of written-off investment
-
-
0
-
Loss on disposal of asset
-210
-
-
-
Revaluation of common stock warrant liability to estimated fair value
-
-
0
-
Gain on sale of lab products business
112,966
-
-
-
Revaluation of contingent consideration to estimated fair value
0
0
156
0
Amortization of premium and accretion of discount on marketable securities, net
-502
-912
220
-931
Other
-51
33
-
-55
Accounts receivable
-2,040
2,078
-5,306
-19,551
Inventory
-2,272
346
-2,034
252
Accrued royalties
-
-
0
-
Prepaid and other assets
5,495
2,884
-3,946
4,189
Operating leases liabilities, net
-1,404
-1,559
-1,542
-1,502
Accounts payable
1,197
-338
-2,378
1,561
Accrued compensation
17,189
-17,810
14,593
3,865
Accrued and other liabilities
846
10,372
-8,850
-2
Deferred revenue
1
-
-
-174
Deferred taxes
-
-
-17
0
Net cash provided by (used in) operating activities
30,604
4,333
21,363
37,358
Purchase of corporate equity securities
-
-
0
-
Maturities of marketable securities
-
54,728
28,632
31,400
Sale of corporate equity securities
-
-
0
-
Additions of capital expenditures
-
-
1,971
1,305
Acquisition of intangible assets
-
-
0
675
Purchases of marketable securities
0
39,850
61,574
17,071
Maturities of marketable securities
59,744
-
-
-
Sales of marketable securities
114,636
-
-
-
Purchase of long term investment
2,000
-
-
-
Proceeds from sale of lab products business, net
164,792
-
-
-
Acquisition of business, net of cash acquired
-
-
0
-
Additions of property and equipment
1,858
3,819
-
-
Net cash provided by investing activities
280,586
11,059
-34,913
12,349
Proceeds from issuance of common stock under employee stock purchase plan
1,506
991
0
0
Proceeds from exercise of warrants
-
-
0
-
Taxes paid related to net share settlement of restricted stock units
6,017
2,511
1,670
1,147
Proceeds from exercise of stock options
1,245
109
1,413
232
Payment of contingent consideration
0
1,500
0
0
Repurchase and retirement of common stock
12,232
-
12,205
25,563
Net cash used in financing activities
-15,498
-2,911
-12,462
-26,478
Effect of exchange rate changes on cash and cash equivalents
-9
13
6
-6
Net increase (decrease) in cash, cash equivalents and restricted cash
295,683
12,494
-26,006
23,223
Cash, cash equivalents and restricted cash at beginning of period
78,474
65,980
91,986
115,274
Cash, cash equivalents and restricted cash at end of period
374,157
78,474
65,980
91,986
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Total revenue
$131,948K
(-23.00%↓ Y/Y)
Gain on sale of lab
products business
$112,966K
Interest income, net
$1,735K
(-66.29%↓ Y/Y)
Proceeds from sale of lab
products business, net
$164,792K
Sales of marketable
securities
$114,636K
Maturities of marketable
securities
$59,744K
Net income (loss)
$110,636K
(684.73%↑ Y/Y)
Accrued compensation
$17,189K
(189.05%↑ Y/Y)
Stock-based compensation
$10,654K
(-41.96%↓ Y/Y)
Depreciation and
amortization
$2,811K
(-61.61%↓ Y/Y)
Inventory
-$2,272K
(-133.70%↓ Y/Y)
Accounts receivable
-$2,040K
(-187.33%↓ Y/Y)
Amortization of right-of-use
assets
$1,237K
(-53.69%↓ Y/Y)
Accounts payable
$1,197K
(-26.34%↓ Y/Y)
Accrued and other
liabilities
$846K
(-84.74%↓ Y/Y)
Amortization of premium and
accretion of discount on...
-$502K
(10.68%↑ Y/Y)
Loss on disposal of
asset
-$210K
Other
-$51K
(-828.57%↓ Y/Y)
Deferred revenue
$1K
(-99.91%↓ Y/Y)
Canceled cashflow
$136,013K
Net cash provided by
investing activities
$280,586K
(1034.96%↑ Y/Y)
Net cash provided by
(used in) operating...
$30,604K
(283.38%↑ Y/Y)
Canceled cashflow
$58,586K
Canceled cashflow
$119,865K
Personnel cost
$49,033K
(-18.38%↓ Y/Y)
Other segment items
$18,991K
(-4.90%↓ Y/Y)
Cost of test
services, product, and...
$15,516K
(-46.74%↓ Y/Y)
Cost of test
services, product, and...
$14,447K
(-5.41%↓ Y/Y)
Business development and
portfolio optimization...
$11,078K
Stock-based compensation
expense
$10,615K
(-42.17%↓ Y/Y)
Professional and legal fees
$5,861K
(-74.00%↓ Y/Y)
Cost of test
services, product, and...
$4,327K
(-53.84%↓ Y/Y)
Research materials and
clinical trials expense
$4,088K
(-43.47%↓ Y/Y)
Depreciation and
amortization expense
$2,057K
(-65.14%↓ Y/Y)
Net increase
(decrease) in cash, cash...
$295,683K
(735.73%↑ Y/Y)
Canceled cashflow
$15,507K
something is missing
-$54,728K
Purchase of long term
investment
$2,000K
Additions of property and
equipment
$1,858K
Gain on sale of lab
products business
$112,966K
Prepaid and other assets
$5,495K
(31.77%↑ Y/Y)
Operating leases
liabilities, net
-$1,404K
(52.46%↑ Y/Y)
Proceeds from issuance of
common stock under...
$1,506K
(-33.71%↓ Y/Y)
Proceeds from exercise of
stock options
$1,245K
(-69.47%↓ Y/Y)
Net cash used in
financing activities
-$15,498K
(71.54%↑ Y/Y)
Effect of exchange rate
changes on cash and cash...
-$9K
(90.00%↑ Y/Y)
Canceled cashflow
$2,751K
Repurchase and retirement
of common stock
$12,232K
(-75.54%↓ Y/Y)
Taxes paid related to
net share...
$6,017K
(-35.33%↓ Y/Y)
Buy us a coffee
CareDx, Inc. (CDNA)
CareDx, Inc. (CDNA)